



# ACIP COVID-19 Vaccines Work Group

**Robert Schechter, MD, MSc**  
**COVID-19 ACIP Work Group Chair**

Advisory Committee on Immunization Practices Meeting  
April 15, 2025

# 2024–2025 COVID-19 vaccines

- In August 2024, the Food and Drug Administration authorized and approved:
  - Moderna COVID-19 vaccine\* in persons  $\geq 6$  months
  - Novavax COVID-19 vaccine\*\* in persons  $\geq 12$  years
  - Pfizer-BioNTech COVID-19 vaccine\* in persons  $\geq 6$  months

\*Omicron JN.1 lineage, KP.2 strain

\*\*Omicron JN.1 lineage, JN.1 strain

# 2024–2025 COVID-19 vaccine recommendations


- Everyone aged  $\geq 6$  months should receive 2024–2025 COVID-19 vaccination
  - Children aged 6 months–4 years need multiple doses of COVID-19 vaccines to be up to date, including at least 1 dose of 2024–2025 COVID-19 vaccine
  - People aged 5-64 years should get 1 dose<sup>1</sup> of 2024-2025 COVID-19 vaccine
  - People who are  $\geq 65$  years<sup>2</sup> and people  $\geq 6$  months of age with moderate or severe immunocompromise<sup>3</sup> should receive a second dose of 2024–2025 COVID-19 vaccine 6 months after their first 2024–2025 dose (minimum interval of 2 months)
  - People with moderate or severe immunocompromise may receive additional doses of 2024–2025 COVID-19 vaccines under shared clinical decision-making (minimum interval of 2 months)

1. People who are unvaccinated and receive Novavax COVID-19 vaccine for initial vaccination should receive 2 doses of 2024–2025 Novavax COVID-19 vaccine

2. People who are unvaccinated and receive Novavax COVID-19 vaccine for initial vaccination should receive 2 doses of 2024–2025 Novavax COVID-19 vaccine followed by a third dose of any 2024–2025 COVID-19 vaccine dose 6 months (minimum interval 2 months) after the second dose.

3. If previously unvaccinated or receiving initial vaccination series, at least 2 doses of 2024–2025 vaccine are recommended, and depending on vaccination history more may be needed. This additional 2024–2025 vaccine dose is recommended 6 months (minimum interval 2 months) after completion of initial vaccination series.


# Provisional Weekly COVID-19 Deaths in the United States Reported to CDC, by Week October 2021–March 2025



[https://covid.cdc.gov/covid-data-tracker/#trends\\_weeklydeaths\\_select\\_00](https://covid.cdc.gov/covid-data-tracker/#trends_weeklydeaths_select_00)

Accessed April 4, 2025

# Weekly rates of COVID-19 associated hospitalizations by season – COVID-NET



<https://www.cdc.gov/covid/php/covid-net/index.html>

Accessed April 4, 2025

# Preliminary Estimates of Disease Burden, October 1, 2024 through March 22, 2025


Disease	Illnesses	Outpatient Visits	Hospitalizations	Deaths
<b>COVID-19<sup>1</sup></b>	7.7 – 13.5 Million	1.9 – 3.2 Million	220,000 – 370,000	26,000 – 43,000
<b>Influenza<sup>2</sup></b>	44 – 76 Million	20 – 34 Million	580,000 – 1.2 Million	25,000 – 120,000

1 <https://www.cdc.gov/covid/php/surveillance/burden-estimates.html>

2 <https://www.cdc.gov/flu-burden/php/data-vis/2024-2025.html>

Accessed April 4, 2025

# COVID-19 vaccination coverage among adults 18 years and older, 2023–2024 through 2024–2025



Current season week ending date refers to the 2024-2025 season only. For the 2023-2024 season, the corresponding week is represented. 2024-2025 vaccines were available starting August 22, 2024. 2023-2024 vaccines were available starting September 12, 2023.

<https://www.cdc.gov/covidvaxview/weekly-dashboard/adult-vaccination-coverage.html>

Accessed April 4, 2025

# ACIP COVID-19 Work Group Meeting Review

## November 2024 – April 2025

- **Considerations for a risk-based and universal vaccine recommendation for the 2025–2026 COVID-19 vaccines**
- COVID-NET data for those with and without risk factors
- COVID-19 mortality
- COVID-19 vaccine hesitancy and uptake
- COVID-19 vaccine safety and effectiveness
- Moderna mRNA-1283 COVID-19 vaccine candidate
- Seroprevalence of SARS-CoV-2
- Post-COVID conditions (Long COVID)
- Multisystem Inflammatory Syndrome in Children (MIS-C)
- Feedback from liaison organizations

# Agenda: April 15, 2025

**Introduction**

**Dr. Robert Schechter (ACIP, WG Chair)**

**Moderna mRNA-1283 COVID-19  
vaccine candidate**

**Dr. Bishoy Rizkalla**

**Epidemiology and risk factors for  
COVID-19 hospitalizations**

**Dr. Fiona Havers**

**Vaccine effectiveness update**

**Dr. Ruth Link-Gelles**

**Work Group Considerations for use  
of 2025–2026 COVID-19 vaccines**

**Dr. Lakshmi Panagiotakopoulos**

# Preliminary Timeline, 2025–2026 COVID-19 Vaccines

- **Today's meeting:** Update on ongoing review of considerations for use of 2025–2026 COVID-19 vaccines
- **Spring:** Anticipated FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting to discuss and make recommendations on strain selection for 2025–2026 COVID-19 vaccines
- **June ACIP meeting:** Discussion and vote on recommended use of the 2025–2026 vaccine
- **Late summer/early fall:** Anticipated 2025–2026 COVID-19 vaccine availability

# Work Group members

## ACIP members

- Robert Schechter (chair)
- Noel Brewer
- Oliver Brooks
- George Kuchel
- Keipp Talbot

## Ex-officio/government members

- BARDA: Christine Oshansky
- CDC: Alan Lam
- FDA: Adam Spanier, Rachel Zhang
- IHS: Uzo Chukwuma
- NIH: Chris Roberts

## CDC co-Leads

- Lakshmi Panagiotakopoulos
- Lauren Roper

## Liaisons

- AAFP: Jonathan Temte
- AAP: Sean O'Leary
- ACOG: Naima Joseph, Laura Riley (alternate)
- ACP: Jason Goldman
- AGS: Ken Schmader
- AIM: Heather Roth
- AMA: Sandra Fryhofer
- ANA: Ruth Francis
- APhA: Richard Dang
- ASTHO: Marcus Plescia
- CSTE: Paul Cieslak, Christine Hahn
- IDSA: James McAuley
- NACCHO: Matt Zahn

## Liaisons, cont'd

- NACI: Eva Wong, Matthew Tunis (alternate)
- NFID: Robert Hopkins, Bill Schaffner (alternate)
- SHEA: Preeti Mehrotra, Marci Drees (alternate)

## Consultants

- Ed Belongia
- Hank Bernstein
- Matthew Daley
- Lisa Jackson
- Jennifer Nelson
- Stanley Perlman
- Peter Szilagyi

# CDC participants

- Amadea Britton
- Mary Chamberland
- Fatimah Dawood
- Nicole Dowling
- Jonathan Duffy
- Kristen Folsom
- Molly Gaines-McCollom
- Julianne Gee
- Monica Godfrey
- Susan Goldstein
- Lisa Grohskopf
- Demorah Hayes
- Suzanne Heitfeld
- Michele Hlavsa
- Jefferson Jones
- Ruth Link-Gelles
- Jessica MacNeil
- Josephine Mak
- Seth Abram Meador
- Michael Melgar
- Sarah Meyer
- Noelle-Angelique Molinari
- Danielle Moulia
- Ismael Ortega-Sanchez
- Manisha Patel
- Pragna Patel
- Amanda Payne
- Jamison Pike
- Hannah Rosenblum
- Sierra Scarbrough
- John Su
- Diya Surie
- Natalie Thornburg
- Melinda Wharton
- Trang Wisard
- JoEllen Wolicki

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [cdc.gov](https://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention.

